These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 32274540

  • 1. [Treatment of metastatic, castration-resistant prostate cancer].
    von Amsberg G, Merseburger AS.
    Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
    [Abstract] [Full Text] [Related]

  • 2. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [Abstract] [Full Text] [Related]

  • 3. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 4. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [Abstract] [Full Text] [Related]

  • 5. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [Abstract] [Full Text] [Related]

  • 6. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ, Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [Abstract] [Full Text] [Related]

  • 7. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
    Lebdai S, Basset V, Branchereau J, de La Taille A, Flamand V, Lebret T, Murez T, Neuzillet Y, Ploussard G, Audenet F.
    World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956
    [Abstract] [Full Text] [Related]

  • 8. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [Abstract] [Full Text] [Related]

  • 9. Perspectives on treatment of metastatic castration-resistant prostate cancer.
    Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM, European Treatment Practices Group.
    Oncologist; 2013 Apr; 18(5):558-67. PubMed ID: 23671006
    [Abstract] [Full Text] [Related]

  • 10. Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic.
    Rahnama'i MS.
    Am J Mens Health; 2022 Apr; 16(4):15579883221115593. PubMed ID: 35950609
    [Abstract] [Full Text] [Related]

  • 11. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T, Hongo H, Oya M.
    BMC Cancer; 2019 Jun 11; 19(1):562. PubMed ID: 31185946
    [Abstract] [Full Text] [Related]

  • 12. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
    Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI.
    JAMA Oncol; 2018 Oct 01; 4(10):1344-1351. PubMed ID: 29978216
    [Abstract] [Full Text] [Related]

  • 13. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Massard C, Mateo J, Loriot Y, Pezaro C, Albiges L, Mehra N, Varga A, Bianchini D, Ryan CJ, Petrylak DP, Attard G, Shen L, Fizazi K, de Bono J.
    Ann Oncol; 2017 Jan 01; 28(1):90-95. PubMed ID: 28039155
    [Abstract] [Full Text] [Related]

  • 14. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
    Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier É, Deville JL, Goupil MG, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthelemy P, Sella A, Fizazi K, Baciarello G, Fererro JM, Laguerre B, Verret B, Hans S, Oudard S.
    Eur Urol Oncol; 2018 Dec 01; 1(6):467-475. PubMed ID: 31158090
    [Abstract] [Full Text] [Related]

  • 15. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.
    Prostate; 2018 Sep 01; 78(13):1035-1041. PubMed ID: 29882332
    [Abstract] [Full Text] [Related]

  • 16. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
    Cursano MC, Iuliani M, Casadei C, Stellato M, Tonini G, Paganelli G, Santini D, De Giorgi U.
    Crit Rev Oncol Hematol; 2020 Feb 01; 146():102864. PubMed ID: 31986318
    [Abstract] [Full Text] [Related]

  • 17. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
    Tassinari D, Cherubini C, Roudnas B, Tamburini E, Drudi F, Bianchi E, Fantini M, Montanari F, Sartori S.
    Rev Recent Clin Trials; 2018 Feb 01; 13(3):226-237. PubMed ID: 29623850
    [Abstract] [Full Text] [Related]

  • 18. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Mizokami A, Kadono Y, Kitagawa Y, Izumi K, Konaka H.
    Int J Urol; 2017 Aug 01; 24(8):566-572. PubMed ID: 28577511
    [Abstract] [Full Text] [Related]

  • 19. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
    Schmidt A, Anton A, Shapiro J, Wong S, Azad A, Kwan E, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua AM, Pook D, Gibbs P, Tran B, Weickhardt A.
    Asia Pac J Clin Oncol; 2021 Feb 01; 17(1):36-42. PubMed ID: 32970925
    [Abstract] [Full Text] [Related]

  • 20. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K.
    Lancet Oncol; 2017 Nov 01; 18(11):1532-1542. PubMed ID: 29033099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.